Effects of a Fixed-Dose Combination Strategy on Adherence and Risk Factors in Patients With or at High Risk of CVD: The UMPIRE Randomized Clinical Trial

Simon Thom, MB, BS, MD; Neil Poulter, MB, MSc, FMedSci; Jane Field, BSc; Anushka Patel, MD, PhD; Dorairaj Prabhakaran, MD, DM, MSc; Alice Stanton, MB, BS, PhD; Diederick E. Grobbee, MD, PhD; Michiel L. Bots, MD, PhD; K. Srinath Reddy, MD, DM; Raghu Cidambi, LLB; Severine Bompoint, BSc; Laurent Billot, MSc; Anthony Rodgers, MD, PhD; for the UMPIRE Collaborative Group

**IMPORTANCE** Most patients with cardiovascular disease (CVD) do not take recommended medications long-term. The use of fixed-dose combinations (FDCs) improves adherence in several clinical areas. Previous trials of cardiovascular FDCs have assessed short-term effects compared with placebo or no treatment.

**OBJECTIVE** To assess whether FDC delivery of aspirin, statin, and 2 blood pressure–lowering agents vs usual care improves long-term adherence to indicated therapy and 2 major CVD risk factors, systolic blood pressure (SBP) and low-density lipoprotein cholesterol (LDL-C).

**DESIGN, SETTING, AND PARTICIPANTS** The UMPIRE trial, a randomized, open-label, blinded-end-point trial among 2004 participants with established CVD or at risk of CVD enrolled July 2010–July 2011 in India and Europe. The trial follow-up concluded in July 2012.

**INTERVENTIONS** Participants were randomly assigned (1:1) to an FDC-based strategy (n=1002) containing either (1) 75 mg aspirin, 40 mg simvastatin, 10 mg lisinopril, and 50 mg atenolol or (2) 75 mg aspirin, 40 mg simvastatin, 10 mg lisinopril, and 12.5 mg hydrochlorothiazide or to usual care (n=1002).

**MAIN OUTCOMES AND MEASURES** Adherence to medication (defined as self-reported use of antiplatelet, statin, and ≥2 BP-lowering medications) and changes in SBP and LDL-C from baseline.

**RESULTS** At baseline, mean BP was 137/78 mm Hg, LDL-C was 91.5 mg/dL, and 1233 (61.5%) of 2004 participants reported use of antiplatelet, statin, and ≥2 BP-lowering medications. Median follow-up was 15 months (interquartile range, 12-18 months). The FDC group had improved adherence vs usual care (86% vs 65%; relative risk [RR] of being adherent, 1.33; 95% CI, 1.26-1.41; P < .001) with concurrent reductions in SBP (−2.6 mm Hg; 95% CI, −4.0 to −1.1 mm Hg; P < .001) and LDL-C (−4.2 mg/dL; 95% CI, −6.6 to −1.9 mg/dL; P < .001) at the end of the study. Although there was consistency of effects across predefined subgroups, evidence existed of larger benefits in patients with lower adherence at baseline. In this subgroup of 727 participants (36%), adherence at the end of study was 77% vs 23% (RR, 3.35; 95% CI, 2.74-4.09; P < .001 for interaction), SBP was reduced by 4.9 mm Hg (95% CI, 7.3-2.6 mm Hg; P = .01 for interaction), and LDL-C was reduced by 6.7 mg/dL (95% CI, 10.5-2.8 mg/dL; P = .11 for interaction). There were no significant differences in serious adverse events or cardiovascular events (50 [5%] in the FDC group and 35 [3.5%] in the usual care group; RR, 1.45; 95% CI, 0.94-2.24; P=.09) between the groups.

**CONCLUSIONS AND RELEVANCE** Among patients with or at high risk of CVD, use of an FDC strategy for blood pressure, cholesterol, and platelet control vs usual care resulted in significantly improved medication adherence at 15 months and statistically significant but small improvements in SBP and LDL-C.

**TRIAL REGISTRATION** clinicaltrials.gov Identifier: NCT01057537


Author Affiliations: Author affiliations are listed at the end of this article.

Group Information: The UMPIRE Collaborative Group members are listed at the end of this article.

Corresponding Author: Simon Thom, MB, BS, MD, International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, 59 N Wharf Rd, London W2 1NY, England (s.thom@imperial.ac.uk).
The long-term use of cardiovascular disease (CVD) preventive therapy is low among people with established disease.1 This shortfall is greatest in low- and middle-income countries, but even in high-income countries treatment coverage in the community is only about 50% in those with coronary disease and 35% in those with stroke.1 People who are at similar risk but have not reached the clinical threshold of experiencing a CVD event are even less likely to be adequately treated.2 Fixed-dose combination (FDC) therapy may reduce these treatment gaps by reducing cost, complexity, therapeutic inertia, and low adherence. However, FDCs could lead to suboptimal risk factor control as a result of reduced tailoring of individual medications, and concerns have been expressed that lifestyle measures could be neglected or medications not restarted if the FDC is stopped. The balance of these potential benefits and risks remains uncertain.

Some trial data are available on antiplatelet, statin, and blood pressure (BP)-lowering FDCs, but these trials were mostly short-term and in populations with low to moderate CVD risk.3–7 Despite recommendations,8 no evidence has been generated on benefits or risks of an FDC-based strategy among individuals with established CVD, for whom there is no contention about the indications for use of all the medication components.9–11 This patient population was the first suggested12–14 for a treatment that has come to be known as the polypill.12 In 2009, the European Commission called for research testing a treatment strategy “that combines existing safe and effective drugs for treating chronic diseases in a single daily pill,” stipulating that “this fixed-dose-combination pill should be low-cost and suitable for production and widespread use in resource-poor countries” and that the work should “address two major challenges of effective secondary prevention and treatment of chronic diseases: adherence and access to treatment in developing countries.” The UMPIRE (Use of a Multi-drug Pill in Reducing Cardiovascular Events) trial was designed in response to this funding call.

Methods

Study Design and Conduct

The UMPIRE trial protocol has been previously described15 and is available at www.spacecollaboration.org along with the protocols of related trials running in parallel.16,17 Ethics approval was granted by the relevant committees in each participating country.

We conducted a randomized, open-label, blinded-endpoint clinical trial of an FDC-based treatment strategy compared with usual care in participants with established CVD or an estimated 5-year CVD risk of 15% or greater in India and in 3 European countries (England, Ireland, and the Netherlands). Participants gave written informed consent and were randomly assigned to continuation with usual care or to an FDC-based treatment strategy with follow-up planned between 12 and 24 months. The primary objective was to assess whether provision of an FDC compared with usual medications improves adherence to indicated therapy and 2 major cardiovascular risk factors: systolic BP (SBP) and low-density lipoprotein cholesterol (LDL-C).

Participants

Men and women aged 18 years or older with high cardiovascular risk, defined as either established CVD (history of coronary heart disease, ischemic cerebrovascular disease, or peripheral vascular disease) or an estimated 5-year CVD risk of 15% or greater,18 were eligible; the risk score included age, sex, SBP, ratio of total to high-density lipoprotein cholesterol (HDL-C), diabetes, smoking, and a 5% adjustment for people from the Indian subcontinent. There had to be clear indications with no contraindications for the components of at least 1 of 2 FDC formulations (see below). Individuals were excluded if alteration of medications was clinically inappropriate or the patient was considered unlikely to follow the trial procedures, including attending scheduled visits. Participants in Europe were recruited via research databases, hospital clinics, and general practice registries at 3 trial centers in London, England; Dublin, Ireland; and Utrecht, the Netherlands. Indian participants were recruited via hospital specialist clinics in 28 centers across the country.

Treatment and Randomization

Randomization to FDC or usual care was conducted in a 1:1 ratio and allocation was stratified by site and by the presence or absence of established CVD using a web-based clinical data management system (InForm; PhaseForward Inc). Participants randomized to usual care continued to be treated at the discretion of their usual physician. Participants randomized to the FDC strategy were prescribed 1 of 2 FDC formulations chosen by the trial physician: version 1 (aspirin, 75 mg; simvastatin, 40 mg; lisinopril, 10 mg; and atenolol, 50 mg) or version 2 (aspirin, 75 mg; simvastatin, 40 mg; lisinopril, 10 mg; and hydrochlorothiazide, 12.5 mg). The FDC was taken once daily, with timing suggested by the physician. Physicians could, at their discretion, add additional medications, stop the FDC and begin treatment with separate medications, or switch FDCs. Because of requirements of local ethics committees, participants in the FDC group were dispensed study FDC treatment from their trial center free of charge as 6-monthly supplies. Participants in the usual care group acquired their medications subject to local payments or exemptions and according to usual dispensing schedules (typically 3-monthly). Eligibility for exemption from prescription or medication charges was assessed at randomization.

Trial Procedures

The minimum planned follow-up time was 1 year. The end-of-study visit for all participants was scheduled to take place about 12 months after the randomization of the last participant into the trial, and all participants were followed up for as long as possible within that interval, with a range of follow-up

| CVD | cardiovascular disease |
| FDC | fixed-dose combination |
| HDL-C | high-density lipoprotein cholesterol |
| LDL-C | low-density lipoprotein cholesterol |
| SBP | systolic blood pressure |
of 12 to 24 months. Participants attended clinic visits for randomization, at 12 months, and at the end of the study. Telephone or clinic visits were conducted at 1 month, 6 months, and 18 months (if applicable). Blood pressure and fasting lipid levels were measured at baseline, at 12 months, and at the end of the study. Blood pressure and heart rate measurements were made with electronic devices (Omron 705CP II) and paper printouts were logged. Fasting blood samples were analyzed by local laboratories. Self-reported adherence to all medications was recorded as the number of days medication was taken in the week prior to the visit (value between 0-7 days). During trial contacts, the research team asked about barriers to adherence, quality of life (measured using the self-administered EQ-5D questionnaire19), cardiovascular and other serious adverse events, and reasons for stopping cardiovascular medications.

Outcomes

Primary outcomes included adherence to indicated medications (self-reported current use of antiplatelet, statin, and ≥2 BP-lowering therapies, defined as taking the medication for at least 4 days during the week preceding the visit) at baseline and at the end of the trial and changes in SBP and LDL-C from baseline to the end of the trial.

Secondary outcomes included adherence at 12 months, reasons for stopping cardiovascular medications, quality of life, serious adverse events, and changes in total cholesterol, HDL-C, triglycerides, and creatinine from baseline to 12 months and end of study and cardiovascular events (including coronary heart disease, heart failure leading to death or hospital admission, and cerebrovascular or peripheral arterial disease events).15

Statistical Analysis

The sample size of 1000 participants in Europe and 1000 participants in India provided 90% power (α = .05) within each region (Europe and India) to detect absolute differences of 3 mm Hg in SBP, 7.7 mg/dL in LDL-C (to convert LDL-C to mmol/L, multiply by 0.0259), and 10 percentage points in rates of adherence to indicated medication (either as FDC or separate antiplatelet, statin, and ≥2 BP-lowering medicines) between the intervention and control groups at the end of the trial. The pre-specified primary analysis was to evaluate the effects across both Europe and India combined, and the trial had 90% power overall to detect differences of 2.2 mm Hg in SBP, 4.7 mg/dL in LDL-C, and 8 percentage points in adherence. These estimates all assumed SDs of 14 mm Hg and 30.9 mg/dL in SBP and LDL-C, respectively, a 50% adherence rate in the usual care group, and up to 10% of patients having died or been lost to follow-up.

The primary analysis of mean differences in changes in SBP and LDL-C at the end of study between the FDC and usual care groups was conducted using analysis of covariance including the randomized treatment and either baseline SBP or baseline LDL-C. Relative risks (RRs) of self-reported adherence to indicated medications at the end of the study were calculated using log-binomial regression including randomized treatment. Adjusted analyses included randomized treatment, baseline value (either SBP, LDL-C, or baseline adherence) plus age, sex, country, and established disease as covariates.

Longitudinal analyses using generalized linear models with a compound-symmetry covariance structure were used as sensitivity analyses for the 3 primary end points. The models included all values collected during follow-up. Because the end-of-study visit could happen at any time from month 12 onward, data collected at the end-of-study visit were reallocated to 1 of the possible scheduled visits (months 12, 18, or 24). Models included randomized treatment, visit, treatment × visit interaction, and for SBP and LDL-C, the corresponding baseline value. Region, baseline adherence to indicated medications, established CVD, age, sex, diabetes mellitus, smoking, and economic stratum were used to predefine subgroup analyses. For each subgroup, we repeated the primary analysis with the addition of the subgroup variable along with its interaction with treatment. Heterogeneity was assessed based on the significance of the interaction term. Continuous secondary end points including diastolic BP, HDL-C, total cholesterol, triglycerides, creatinine, quality-of-life scores, anthropometric measurements, and lifestyle factors were assessed using analysis of covariance. Differences in incidence of cardiovascular outcomes were analyzed using Cox models after checking the proportional hazard assumption.

All analyses were conducted on an intention-to-treat basis with no imputation of missing data. A 2-sided P<.05 was used to indicate statistical significance for all tests. Although formal adjustments for multiple tests were not made, findings are interpreted in light of the number of comparisons made and the level of significance of the result.

Results

Baseline Characteristics of Trial Participants and Trial Structure

A total of 2138 potential participants were screened, 134 were ineligible and 2004 were randomized (1000 in India and 1004 in Europe) between July 2010 and July 2011 (Figure 1). Among the 1002 participants randomized to the FDC group, physicians started therapy with FDC version 1 for 589 (58.8%) and FDC version 2 for 413 (41.2%). Baseline characteristics of the FDC and usual care groups were similar (Table 1), with no major baseline imbalances. The majority of participants (n=1771 [88%]) were included on the basis of established CVD. Table 1 also describes the use of prerandomization antiplatelet, statin, and BP-lowering medicines, showing that the entire group had a high level of adherence to the indicated medications (n=1233 [61.5%] at the outset). At baseline, reported use of antiplatelet therapy (n=1832 [91.4%]), statins (n=1760 [87.8%]), and BP-lowering therapy (n=1862 [92%]) was high, although levels were lower for those reporting 2 or more BP-lowering drugs 1371 (68.4%). The median duration of follow-up was 15 months (interquartile range, 12-18 months) for both groups, and follow-up concluded in July 2012. One hundred sixty-three participants missed at least 1 visit and of these, 68 came to a subsequent visit. At the end of the study, data on self-reported adherence, systolic BP, and LDL-C were available for 1921 (96%),...
1849 (92%), and 1807 (90%) randomized participants, respectively (Figure 1). Nine hundred sixty-six participants (48%) reported exemption from prescription or medication charges (Table 1).

### Overall Effects on Primary Outcomes of Adherence, SBP, and LDL-C

At the end of the study, 829 (86.3%) of 961 participants in the FDC group were continuing with indicated medications compared with 621 (64.7%) of 960 in the usual care group (unadjusted RR, 1.33; 95% CI, 1.26-1.41; P < .001) (Table 2 and Figure 2A). In absolute terms, this amounted to a 21.6% difference (95% CI, 17.8%-25.3%; P < .001) in treatment rates and a number needed to treat of 4.6 patients (95% CI, 4.0-5.6 patients). For each treatment mode, there was an increase in treatment rates after randomization of about 5% in participants in the usual care group who were prescribed additional individual medications and a larger absolute increase in the FDC group as a result of FDC initiation. In the usual care group, adherence to each treatment mode decreased slightly over time but remained higher than baseline at 18 months. At 1 month, use of indicated medications in the FDC group was 97.3% compared with 68.3% in the usual care group. The absolute difference between groups decreased slightly by 6 months and
remained approximately constant thereafter. The decrease between 1 and 6 months in the FDC group largely occurred among patients who were not adherent at baseline; of the 56 who stopped FDC during this period, 40 (71.4%) were not adherent at baseline. At the end of the study, FDC use was reported in 747 (77.7%) of 961 participants in the FDC group, with a further 82 (8.5%) adhering to their indicated medications by taking separate tablets.

An alternate definition of adherence involving taking antiplatelet, statin, and at least 1 BP-lowering drug also showed benefit (873/961 [90.8%] in the FDC group vs 808/960 [84.2%] in the usual care group; \( P < .001 \)) owing to improved adherence to antiplatelet and statin therapy (there was no difference in the proportion taking at least 1 BP-lowering drug at the end of the study [95.2% vs 95.9%]). A sensitivity analysis of the adherence definition was performed using 2 alternative definitions at the end of the study, one based on taking indicated medications on 1 day or more in the last week and another based on taking medications every day of the last week. The RR for adherence associated with the FDC group using 1 day or more was 1.33 (95% CI, 1.26-1.40) and the RR using 7 days was 1.41 (95% CI, 1.33-1.49). These did not differ from the RR using the definition of 4 or more days (RR, 1.33; 95% CI, 1.26-1.41).

Table 2 shows mean differences in the changes in SBP and LDL-C using the primary analysis of covariance method. Overall, SBP (−2.6 mm Hg; 95% CI, −4.0 to −1.1 mm Hg) and LDL-C (−4.2 mg/dL; 95% CI, −6.6 to −1.9 mg/dL) levels were modest but significantly lower in the FDC group compared with the usual care group at the end of the study. Figure 3 shows changes over time and overall differences using a longitudinal generalized linear model. For this analysis, overall mean differences over time were −3.3 mm Hg (95% CI, −4.6 to −1.9 mm Hg; \( P < .001 \)) for SBP and −5.3 mg/dL (95% CI, −7.5 to −3.2 mg/dL; \( P < .001 \)) for LDL-C.

Adjusted models including randomized treatment, baseline value, country, history of CVD, age, and sex are shown in Table 1 in the Supplement. Adjusted and unadjusted effects were similar for treatment effect estimates of SBP and LDL-C reduction. However, the adjusted effect for adherence was somewhat lower (RR, 1.13; 95% CI, 1.08-1.18; \( P < .001 \)) than for unadjusted analyses as a result of a small baseline imbalance in use of antiplatelet, statin, and 2 or more BP-lowering agents and the effect modification for this variable (see below).

The effects of the FDC strategy on adherence, SBP, and LDL-C in prespecified subgroups defined by baseline characteristics are shown in Figure 4 and Figure 5. The number of subgroups should be taken into consideration, and across the 3 co-primary end points, the only consistent effect modifier was whether patients were taking antiplatelet, statin, and 2 or more BP-lowering drugs at baseline. This was most marked for the adherence outcome, as it shared the same definition as the effect modifier. For the adherence outcome, effects were statistically significant in every subgroup but were quantitatively larger in patients at high estimated CVD risk (RR, 1.93; 95% CI, 1.51-2.47; \( P < .001 \)), those with low baseline adherence (RR, 3.35; 95% CI, 2.74-4.09; \( P < .001 \)), smokers (RR, 1.69; 95% CI, 1.42-2.02; \( P = .002 \)), and those for whom their physician intended to use FDC version 2 (RR, 1.45; 95% CI, 1.32-1.59; \( P = .02 \)). In terms of SBP reduction, treatment effects were larger in those without baseline adherence to indicated medications (reduced by 4.9 mm Hg; 95% CI, 7.3-2.6 mm Hg; \( P = .01 \)) and in
Table 2. Effect of Treatment on Adherence to Primary and Secondary End Points

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Fixed-Dose Combination (n = 1002)</th>
<th>Usual Care (n = 1000)</th>
<th>Treatment Effect (95% CI)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary end points</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adherence, No./total (%)^b</td>
<td>829/961 (86)</td>
<td>621/960 (65)</td>
<td>1.33 (1.26 to 1.41)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Systolic blood pressure, mm Hg</td>
<td>129.2 (128.1-130.2)</td>
<td>131.7 (130.7-132.8)</td>
<td>-2.5 (-4.0 to -1.1)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Low-density lipoprotein cholesterol, mg/dL</td>
<td>84.2 (82.5-85.8)</td>
<td>88.4 (86.7-90.0)</td>
<td>-4.2 (-6.6 to -1.9)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Secondary end points</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adherence at 12 mo, No./total (%)</td>
<td>827/935 (88)</td>
<td>602/925 (65)</td>
<td>1.36 (1.29 to 1.43)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Diastolic blood pressure, mm Hg</td>
<td>72.8 (72.2-73.5)</td>
<td>75.2 (74.7-73.8)</td>
<td>-2.5 (-3.3 to -1.6)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Total cholesterol, mg/dL</td>
<td>156.6 (154.6-158.5)</td>
<td>159.1 (157.1-161.1)</td>
<td>-2.5 (-3.3 to 0.3)</td>
<td>.08</td>
</tr>
<tr>
<td>High density lipoprotein cholesterol, mg/dL</td>
<td>44.2 (43.7-44.6)</td>
<td>43.7 (43.2-44.2)</td>
<td>0.5 (-0.2 to 1.1)</td>
<td>.14</td>
</tr>
<tr>
<td>Triglycerides, mg/dL</td>
<td>142.3 (137.8-146.9)</td>
<td>138.8 (134.2-143.4)</td>
<td>3.6 (-2.9 to 10.0)</td>
<td>.28</td>
</tr>
<tr>
<td>Plasma creatinine, mg/dL</td>
<td>1.07 (1.06-1.08)</td>
<td>1.04 (1.03-1.05)</td>
<td>0.03 (0.01 to 0.05)</td>
<td>.002</td>
</tr>
</tbody>
</table>

^a Treatment effect: relative risk for adherence and mean difference for blood pressure, cholesterol measures, and creatinine.

^b Self-reported use of antiplatelet, statin, and ≥2 blood pressure-lowering drugs.

Effects on Secondary Outcomes

Creatinine, Glucose, and Other Laboratory Measures

Creatinine increased in both the FDC and usual care groups between baseline and the end of the study (FDC, from 1.01 to 1.07 mg/dL; usual care, from 1.01 to 1.04 mg/dL) and the difference in this increase between the 2 groups was statistically significant (FDC – usual care, 0.03 mg/dL; 95% CI, 0.01-0.05; P = .002) (Table 2). There was also an increase in uric acid in the FDC group (FDC, from 5.6 to 5.9 mg/dL; usual care, from 5.7 to 5.8 mg/dL) and the difference in this increase between the 2 groups was also significant (FDC – usual care, 0.2 mg/dL; 95% CI, 0.1-0.3; P < .001). There were no significant differences between groups in the levels of sodium, potassium, alanine transaminase, aspartate aminotransferase, or glucose at the end of the study (eTable 2 in the Supplement).

Weight, Lifestyle Factors, and Quality-of-Life Scores

Weight, waist circumference, and body mass index did not change during follow-up and did not differ between groups at the end of the study. Self-reported time engaged in vigorous physical activity, participation in exercise programs, attendance at dietetic clinics, and participation in smoking cessation programs were also similar in both groups at the end of follow-up (eTable 3 in the Supplement). Reported time engaged in moderate physical activity was similar in the 2 groups at baseline (FDC, 163 [SD, 179] min/wk vs usual care, 158 [SD, 180] min/wk) but significantly higher in the FDC group than in the usual care group at the end of the study (157 [SD, 178] min/wk vs 141 [SD, 157] min/wk, respectively; P = .03). Quality of life did not differ between the 2 groups at the end of the study, although the EQ-5D visual analog scale score was significantly higher in the FDC group (2.43; 95% CI, 0.87-3.99; P = .002) (eTable 4 in the Supplement).

Reasons for Stopping CVD Medications

Among the 219 participants in the FDC group who discontinued the FDC, the main stated reasons were patient choice (61/219 [28%]), medical advice without specified reason or adverse effect (26/219 [26%]), cough (46/219 [21%]), dizziness (20/219 [9%]), serious adverse events (18/219 [8%]), other adverse events (35/219 [16%]), and other reasons (eg, increased creatinine level, fatigue; 18/219 [8%]). A total of 9 participants switched to the alternative FDC version. Among participants who stopped the FDC during the course of follow-up, 73 (58%) of 126 assessed at month 18 had switched to antplatelet, statin, and BP-lowering therapy via separate medications whereas 26 (21%) of 126 participants were not taking any cardiovascular medications. The medications provided to those who stopped the FDC are described in eTable 5 in the Supplement.

Discussion

To the best of our knowledge, this was the first randomized trial to assess the long-term use of an FDC containing anti-
platelet, statin, and BP-lowering drugs compared with usual care in patients with CVD. The results show that access to FDCs in patients with CVD or similarly high risk improved adherence, BP, and cholesterol levels. The reductions in BP and cholesterol level were small overall in this comparatively well-treated population but were larger in the subgroup not receiving all recommended treatments at baseline.

The trial had several strengths in terms of sample size, duration of follow-up, and completeness of data collection. However, there are several issues to be considered when interpreting results from adherence trials in general and this study in particular. The generalizability of these findings is limited. Participants were selected on the basis of being willing and able to attend study visits, so the recruited population is not nec-

At the end of the study (median, 15 months), there was a 21% (P < .001) difference in reported adherence for indicated medications (fixed-dose combination [FDC], 86% - usual care [65%]; all 4 medication types). The end-of-study differences (FDC - usual care) were smaller for each class: statins, 2% (93% - 91%; P = .08); antiplatelet drugs, 1% (94% - 93%; P = .43); and 2 or more blood pressure (BP) - lowering drugs, 15% (89% - 74%; P < .001). Overall relative risk was obtained via repeated log-binomial regression using a covariance matrix with a compound-symmetry structure (panel A only). Estimates combine all nonmissing values collected at months 1, 6, 12, 18, and 24. Model terms include treatment, month, and treatment × month interaction. Dashed lines indicate 95% confidence bands.
were observed compared with a usual care group in whom adherence was reported at baseline compared with the general population. However, improvements in adherence rates are typically reported for antiplatelet, statin, and BP-lowering drug treatments, whereas comparable combination treatment rates are generally not taken indicated medications at baseline. In this group, randomizedization to FDC resulted in a 3-fold increase in adherence levels (77% vs 23%) and larger reductions in SBP and LDL-C. Effects were observed in a trial population of whom 82% initially reported use of antiplatelet, statin, and BP-lowering drug treatments, whereas comparable combination treatment rates are around 50% in high-income countries and 5% to 20% in low- and middle-income countries. Furthermore, improvements were observed compared with a usual care group in whom treatment rates increased initially and remained higher than baseline throughout the study, whereas adherence typically reduces over time.21,22

The primary outcome of adherence (defined as taking statin, antiplatelet, and/or blood pressure-lowering drugs at end of study) is shown by prespecified baseline subgroups. Error bars indicate 95% CIs; boxes are placed at the relative risk for and size proportional to the amount of information per subgroup, and vertical dashed lines show the overall effect for each outcome. P values are for the test of homogeneity for each subgroup. FDC indicates fixed-dose combination; CVD, cardiovascular disease. See Methods for descriptions of versions 1 and 2 of FDC.
similar effects of the FDC strategy. Dispensing of medication also differed between the groups. The trial centers were advised to dispense the FDC as a 6-month supply, although in some circumstances in India, where cool storage temperature was a concern, 3-month supplies were issued. Routine prescribing and dispensing practices are varied in both India and Europe, with 3 months being the usual interval of supply. The net effect of the longer dispensing interval for FDC is uncertain, however, because the extended duration of supply was offset by the inconvenience of collection from the distant trial center as opposed to the neighborhood pharmacy. A large US trial recently showed that elimination of co-payments for core cardiovascular medicines improved adherence by about 5% in absolute terms, which is smaller than the treatment effect seen here.23 This presents a potential bias favoring the FDC strategy.

Adherence to medication is determined by complex interactions between health care systems and patients. Adherence may be defined as the extent to which a person’s behav-

The primary outcomes of systolic blood pressure (SBP), and low-density lipoprotein cholesterol (LDL-C) are shown by prespecified baseline subgroups. Error bars indicate 95% CIs, boxes are placed at the relative risk for and sized proportional to the amount of information per subgroup, and vertical dashed lines show the overall effect for each outcome. P values are for the test of homogeneity for each subgroup. FDC indicates fixed-dose combination; CVD, cardiovascular disease. See Methods for descriptions of versions 1 and 2 of FDC.

<table>
<thead>
<tr>
<th>CVD risk</th>
<th>SBP, Mean (SE), mm Hg</th>
<th>Mean Difference (95% CI)</th>
<th>Risk Ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Established CVD</td>
<td>131.3 (0.6) 128.6 (0.6)</td>
<td>-2.7 (-4.2 to -1.1)</td>
<td>Favors FDC P .79</td>
</tr>
<tr>
<td>≥15% 5-y CVD risk</td>
<td>135.4 (1.5) 133.3 (1.5)</td>
<td>-2.0 (-6.3 to 2.2)</td>
<td>Favors FDC P .17</td>
</tr>
</tbody>
</table>

Adherence to indicated medication at baseline

| Yes | 131.7 (0.7) 130.7 (0.7) | -1.0 (-2.9 to 0.8) | P .01 |
| No  | 131.8 (0.9) 126.8 (0.8) | -4.9 (-7.3 to -2.6) | P .03 |

Sex

| Female | 129.9 (1.3) 130.9 (1.2) | 1.0 (-2.5 to 4.4) | P .88 |
| Male   | 132.1 (0.6) 128.8 (0.6) | -3.3 (-4.9 to -1.7) | P .88 |

Diabetes

| Yes | 132.3 (1.0) 131.4 (1.0) | -1.0 (-3.7 to 1.8) | P .93 |
| No  | 131.5 (0.6) 128.6 (0.6) | -3.2 (-4.9 to -1.5) | P .99 |

Smoking

| Yes | 130.5 (1.4) 127.7 (1.5) | -2.8 (-6.7 to 1.2) | P .88 |
| No  | 131.9 (0.6) 129.4 (0.6) | -2.6 (-4.1 to -1.0) | P .88 |

Continent

| Europe | 133.9 (0.7) 132.4 (0.7) | -1.5 (-3.4 to 0.5) | P .88 |
| India  | 129.5 (0.7) 125.7 (0.7) | -3.8 (-5.9 to -1.8) | P .88 |

FDC choice

| Version 1 | 130.8 (0.7) 128.1 (0.7) | -2.7 (-4.5 to -0.8) | P .88 |
| Version 2 | 133.1 (0.8) 130.6 (0.8) | -2.4 (-4.7 to -0.2) | P .88 |

<table>
<thead>
<tr>
<th>CVD risk</th>
<th>LDL-C, Mean (SE), mg/dL</th>
<th>Mean Difference (95% CI)</th>
<th>Risk Ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Established CVD</td>
<td>88.6 (0.9) 84.7 (0.9)</td>
<td>-3.9 (-6.4 to -1.4)</td>
<td>Favors FDC P .43</td>
</tr>
<tr>
<td>≥15% 5-y CVD risk</td>
<td>86.9 (2.5) 80.1 (2.5)</td>
<td>-6.8 (-13.7 to 0.1)</td>
<td>Favors FDC P .11</td>
</tr>
</tbody>
</table>

Adherence to indicated medication at baseline

| Yes | 88.0 (1.1) 85.4 (1.1) | -2.7 (-5.6 to 0.3) | P .14 |
| No  | 89.0 (1.4) 82.3 (1.3) | -6.7 (-10.5 to -2.8) | P .98 |

Sex

| Female | 91.9 (2.0) 83.9 (2.0) | -8.0 (-13.5 to -2.4) | P .11 |
| Male   | 87.6 (0.9) 84.2 (0.9) | -3.4 (-6.0 to -0.8) | P .11 |

Diabetes

| Yes | 86.0 (1.6) 81.9 (1.6) | -4.1 (-8.6 to 0.3) | P .14 |
| No  | 89.3 (1.0) 85.1 (1.0) | -4.2 (-7.0 to -1.5) | P .27 |

Smoking

| Yes | 84.8 (2.3) 84.0 (2.4) | -0.8 (-7.3 to 5.7) | P .92 |
| No  | 88.9 (0.9) 84.2 (0.9) | -4.8 (-7.3 to -2.2) | P .92 |

Continent

| Europe | 86.7 (1.2) 88.6 (1.2) | 1.9 (-1.3 to 5.1) | P .92 |
| India  | 90.2 (1.2) 79.4 (1.2) | -10.8 (-14.1 to -7.4) | P .92 |

FDC choice

| Version 1 | 87.6 (1.1) 83.3 (1.1) | -4.3 (-7.3 to -1.2) | P .92 |
| Version 2 | 89.5 (1.3) 85.4 (1.3) | -4.0 (-7.7 to -0.4) | P .92 |
ior (taking medication) corresponds with agreed recommendations from a clinician, and it is best assessed by a complementary approach using a questionnaire in tandem with objective measures.24 There are several mechanisms whereby an FDC strategy may enhance adherence. These encompass ease of prescription, overcoming physician inertia, patient acceptability, packaged delivery, and ease of taking. This trial has shown that physicians are willing to prescribe an FDC to this group of patients by involving them in the trial, and at the end of the study more patients were taking the combination treatment. The self-reported assessment of adherence is substantiated by the changes in SBP and LDL-C.

In terms of assessing potential risks, the trial was not designed to assess adverse effects of component medications (such as effects on cough, uric acid, and creatinine), which have been established already, but rather assessed the potential risk of an FDC strategy to lead to suboptimal care. One expressed concern is that reduced choice of medications and doses and/or unfamiliarity with use of FDCs as background treatment leads to suboptimal risk factor control; however, this trial suggests that these issues were not sufficient to offset improvements in risk factor control brought about by improved adherence. The trial also demonstrated that this FDC strategy did not lead to deterioration in other key measures relevant to CVD control, such as smoking, weight control, and exercise, even when patients knew they were receiving an FDC. The rate per month of stopping the FDC was about one-fifth that seen in a previous placebo-controlled trial of treatment initiation with one of these FDCs,4 in part because the current trial population had mostly been receiving the component medicines already. One potential concern is the stopping of all medicines if an FDC is stopped because of the adverse effects of 1 component, but this trial showed that separate medicines are routinely started instead.

The trial did not identify an effect on cardiovascular events, but with only 85 events it had insufficient power to detect meaningful differences between groups. If beneficial changes in SBP, LDL-C, and aspirin use of the magnitude observed in this trial were realized in a similar population, it has been estimated that RR reductions of about 15% in coronary artery disease and stroke might be expected after a few years.4 However, a clinical trial would need to observe more than 1000 events to reliably detect an RR reduction of 15%.25 A 2002 joint report by the World Health Organization and Wellcome26 recommended that evaluation of these products in the secondary prevention setting be principally based on bioequivalence (ie, studies showing that the FDC is bioequivalent to the separate components) and evidence of improved adherence (such as improved risk factor control, as seen in this trial), given the extensive evidence of clinical event reduction with the component medicines and drug classes, which has increased in the ensuing decade.26-29

These results should be considered in the context of previous trials showing that FDCs improve adherence.30-32 The results should also be considered in the light of other trials of antiplatelet, statin, and BP-lowering FDCs.3-5,3435 These trials had comparison groups of placebo or no treatment mostly with 12 weeks or less of follow-up and generally showed risk factor reductions of the size expected from individual medications, once dropins and dropouts are accounted for.3,34 This is the first trial to our knowledge evaluating FDC-based care over a prolonged interval in participants with established CVD or at similarly high levels of risk, among whom more than 40% of all cardiovascular events occur.30 This targeted approach to a high-risk population contrasts with the population-wide treatment approach that some have advocated for the polypill.12 These data suggest that FDCs could play a role in increasing uptake of statins, aspirin, and combination blood-pressure-lowering drugs in patients with CVD not currently receiving such treatment. Scaled-up access to core cardiovascular medicines is in keeping with national CVD prevention goals in India, Europe, and the United States27-29 and could contribute importantly to World Health Organization goals for noncommunicable disease control.40

Conclusion

In summary, among patients with or at high risk of CVD, the use of an FDC strategy for BP, cholesterol, and platelet control compared with usual care resulted in significantly improved medication adherence at 15 months.
Fixed-dose combinations used in the UMPIRE trial following a decision by Dr Reddy's Laboratories not to proceed with taking the products to market because of uncertainty in regulatory requirements. No other disclosures were reported.

Funding/Support: The project was funded by the European Commission Seventh Framework Programme (grant 241849). Dr Reddy's Laboratories (Hyderabad, India) provided the FDCs and supported the trial start-up meetings in London and India.

Role of the Sponsor: The UMPIRE trial was designed and conducted by an investigator-led independent steering committee. Dr Reddy's Laboratories had a nonvoting member (Cidambi) on the trial steering committee who had a management role in the design and conduct of the study and reviewed the final manuscript. Neither the European Commission nor Dr Reddy's had any role in the collection, management, analysis and interpretation of the data; they had no role in approval of the manuscript or decision to submit the manuscript for publication. The European Commission had no role in preparation or review of the manuscript.

UMPIRE Collaborative Group: Data and Safety Monitoring Board: Jane Armitage (chair), Yolanda Van de Pandey (statistician). Clinical End-Point Adjudication Committee: Neil Chapman (chair), Ajay Gupta, Michele McGrady, Clara Chow, S. Harikrishnan, Jusoo Makinen, Lucy Perry (statistician), Careen Orsoco (clinical safety team), Elvira Perry (clinical safety team). Expert Advisory Board: Kay Tee Khaw (chair), Raj Tandon, B. Soma Raju, Jeyaprakash Morrell, Stephen E. Shelley, Andrew Tonkin, Tom Gazzano. UMPIRE Collaborative Group: Coordinating office, Imperial College London: Simon Thom (coordinating chief investigator), Neil Poulter (co-principal investigator). Jane Field (project manager), Alison Adderkin (project oversight), Annette Wilson (administration), Joanna Dobson (statistician). Data management and statistical analysis: the George Institute for Global Health, Sydney: Laurent Bilott (trial statistician), Severine Bompont (statistician), Qiang Li (statistician). Dominic Byrnes (data manager), Suzanne Steley (data manager). Coordinating Centres: India: The George Institute for Global Health, Hyderabad: Arunshakti Patel, Abdul Samad, Vipin Patil, Anurag Shrivastava, Sudha Kallakuri, Nityanand Singh, Rama Guggilla, Nitin Patnaik, Manojkumar Rohit, Srinivas Reddy, Ramil Malhotra, Shyambalaji Achuthan, Nusrat Sharif, Postgraduate Institute of Medical Education and Research, Chandigarh; N. Chidambaram, R. Umarani, D. R. Karihalilukey, K. Palaniappan, Annamalai University, Annamalai Nagar: P. P. Mohanan, Divini Davies. West Fort Hi-tech Hospital, Trissur; S. Harikrishnan, G. Sanjay, Suresh Babu, See Chitra Tirunal Institute for Medical Science and Technology, Trivandrum; Abraham Oommen, F. M. Saleem, Kannan, V. Sivasankaran, K. Balamurali, Ramana Maharishi Rangamandal Hospital, Trivuvannamalai; Ashok Kumar Dash, Kalyana Chakravarty, J. Praveenllatha, G. Venkat Prasad, Ashok Kumar Odel, Global Hospitals, Hyderabad; M. Bhaskara Rao, Kodem Damodra Rao, Prathap Chandana Bose, Padmakumar, Department of Cardiology, Care Hospital, Vishakhapatnam; Golla Nagendra Prasad, Anand Kannayay, Sowmya Joy, Gayathri, From, Udayakumar, Chennai, G. Venkateshwar Reddy, Malladi Srinivasa Rao, Andhra Medical College, King George Hospital, Vishakhapatnam; Milind A. Gadkari, Tapan Pillay, Mohd Kishirsagar, Sheetal Karwa, Department of Cardiology, KEM Hospital, Pune; P. V. Raghava Variya, J. Prabha Chandana, S. Anil Kumar, Anjan Kumar, Sathish Kumar, Nagamalleswar Rao, Lalitha Super Special Hospitals, Guntur; Byrrapenani Ramesh Babu, Shashendhu, Murali, Asa Farhana, Kavitha, Priyanka, Peddredddy Jyothsna, Neena Reddy, Medwin Hospital, Hyderabad; Sanjay Mehrotra, Arun Ramamoor Rao, Myfouse Begum, G. Nazia, R. Karthikayanan, Narayana Hrudayalaya, Bangalore; Satej S. Janorlak, Ms. Nikitha Yadav, Deenanath Mangeshkar Hospital and Research Centre, Pune; Damara Seshagiri Rao, Armar Narayang Patnaik, J. L. N. Varma, Nizam's Institute of Medical Sciences, Hyderabad, Sridhoo Joshi, Govinda Pulagam, Madhuri Mahajan, M. Narahari, Maharaj Hospital and Research Centre, Hyderabad; Ballakere Jayaram Subhish, Sandeep, Madan Ramesh, Atiqtulla Shariff, G. Parthasarathi, Jagadguru Sri Shirvaathreeshwara Medical College and Hospital, Mysore; Suhas P. Hardas, Nilesh Savant, Amrutha Sabari, Hall Clinic, Pune, Tilak-Suvanra, Nishan Sidirothu, Archana Chavan, John Mochumur, Hitakshi Trived, Asian Heart Institute and Research Centre, Mumbai; K. Joel Nesaraj, S. Rajasekaran, Rufus Demel, M. Nijanth, Bethesda Hospital, Ambur. Investigator Sites, Europe: Alice Stanton (principal investigator), Brendan McCadam, David Williams, Eamon Dolan, Liam Kavaghan, Ursula Quinn, Lelane Vanderpoel, Benoite Maguire, Kathleen Shortall, Margaret McGrath, Ann Collins, Sandra McCubrig, Barbara Gallagher, Royal College of Surgeons in Ireland, Beaumont and Connolly Hospitals, Dublin, Ireland; Filomena Pacielo (principal investigator), Rebecca James, Jill Bunker, Wendy Callister, Natesha Henry-Mitchell, Judy Mackay, Clinical Investigation Unit, International Centre for Circulatory Health, Imperial College NHS Trust, London, England; Diederick E. Grobbbee (principal investigator), Michael L. Bots (co-principal investigator), Melvin Laferbe, Marcel van Dijk, Wilco Spiereing, Lydeke Zwart, Gerty Van Hemert, Karen Menningha, Fien Stern, Lizeth Vendrig, University Medical Center Utrecht, Utrecht, the Netherlands. SPACE Collaboration: Anthony Rodgers (chair), Anushka Patel (deputy chair), Ruth Webster (coordinator); membership, see www.spacecollaboration.org. The IMPACT trial was the first of the designed trials by the SPACE collaboration and provided the basis for the design of the sister trials, Kanjini GAP and UMPIRE.

Previous Presentation: Presented in part at the American Heart Association Scientific Sessions, Los Angeles, California, on November 5, 2012.

Additional Contributions: We are indebted to the 2138 individuals who volunteered as participants in this trial.

Correction: This article was corrected on September 25, 2013, to correct misspelled and omitted names in the UMPIRE group.

REFERENCES


